Australian Clinical Labs Ltd (AU:ACL) has released an update.
UBS Group AG, a substantial holder in Australian Clinical Labs Limited, has reduced its voting power from 7.74% to 5.43% as of September 13, 2024. The change reflects a decrease in the number of ordinary shares held, impacting the group’s voting influence within the company. This shift in share distribution could be of interest to investors monitoring Australian Clinical Labs’ shareholder landscape and potentially affecting stock performance.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.
